公开(公告)号：EP1517688A2

公开(公告)日：2005-03-30

申请号：EP03760622.5

申请日：2003-06-16

申请人： Solvay Pharmaceuticals GmbH

发明人： RUPP, Heinz ,  EISELE, Bernd ,  ZIEGLER, Dieter ,  JÄGER, Bodo ,  MAISCH, Bernhard

IPC分类号： A61K31/421 ,  A61K31/506 ,  A61K31/47 ,  A61K31/496 ,  A61P19/00 ,  A61P1/00 ,  A61P25/00

CPC分类号： A61K31/4178 ,  A61K31/421 ,  A61K31/47 ,  A61K31/496 ,  A61K31/506

摘要： Disclosed is the use of selective imidazoline receptor agonists, particularly moxonidine, rilmenidine, LNP-509, S-23515, PMS-812, PMS-847, and BU-98008, and the physiologically acceptable salts thereof, for the production of pharmaceutical preparations used for treating and/or preventing functional disturbances and/or diseases in larger mammals or humans, which require inhibition or a reduction in the activity of proteins that regulate the intracellular pH value and belong to the superfamily of bicarbonate transporters, particularly diseases which affect the bones as a result of an undesired bone resorption level, especially osteoporosis, diseases of the gastrointestinal tract, especially gastric ulcers, and neural and/or neuropsychiatric diseases that are related to a pathologically modified, preferably an increased, neural activity, preferably depression, Alzheimer's, eating disorders, and schizophrenia.